Zeigler Z R, Jones D, Rosenfeld C S, Shadduck R K
Western Pennsylvania Cancer Institute, Western Pennsylvania Hospital, Pittsburgh 15224.
Stem Cells. 1993 Jan;11(1):49-55. doi: 10.1002/stem.5530110109.
Sixteen patients (ages 53 to 85) with myelodysplastic syndrome (MDS) were treated with recombinant human erythropoietin (rHuEPO) to observe its effects on hematopoiesis. All were transfusion dependent and had Hb levels less than 9.0 g/dl and less than 10% marrow blasts. Eight patients had refractory anemia (RA), one had refractory anemia with excess blasts (RAEB), and seven had refractory anemia with ringed sideroblasts (RARS). A response was defined as an increase in Hb by greater than 2 g/dl and/or a decrease in transfusion requirement by greater than 50%. Patients were considered to be evaluable if on study greater than two months. Three of thirteen evaluable patients had a response. One patient with RA had a sustained trilineage hematologic response with no evidence of disease progression. None of the patients had trouble with hypertension or with thrombotic events. This suggests than an occasional patient with MDS will respond to rHuEPO. In some patients, this may be beneficial clinically.
16例年龄在53至85岁之间的骨髓增生异常综合征（MDS）患者接受了重组人促红细胞生成素（rHuEPO）治疗，以观察其对造血的影响。所有患者均依赖输血，血红蛋白（Hb）水平低于9.0 g/dl，骨髓原始细胞少于10%。8例患者为难治性贫血（RA），1例为难治性贫血伴原始细胞增多（RAEB），7例为难治性贫血伴环形铁粒幼细胞（RARS）。缓解定义为Hb升高超过2 g/dl和/或输血需求减少超过50%。如果患者研究时间超过两个月，则被认为可评估。13例可评估患者中有3例出现缓解。1例RA患者有持续的三系血液学缓解，无疾病进展证据。所有患者均未出现高血压或血栓事件问题。这表明偶尔有MDS患者会对rHuEPO产生反应。在一些患者中，这在临床上可能是有益的。
